Stroke, a leading cause of long-term disability and death worldwide, is a medical emergency that necessitates immediate attention. Early recognition and management can significantly improve patient outcomes.
Healthcare professionals must be adept at identifying the hallmark signs of stroke, which are encapsulated in the acronym FAST: Face drooping, Arm weakness, Speech difficulties, and Time to call emergency services. Additionally, symptoms such as sudden confusion, trouble seeing, loss of balance, and severe headache with no known cause should raise suspicion.
Understanding the two main stroke subtypes, ischemic and hemorrhagic, is crucial for targeted management. Ischemic strokes, caused by blood clots obstructing cerebral blood flow, account for approximately 87% of all strokes. Hemorrhagic strokes, caused by ruptured blood vessels in the brain, are less common but more deadly.
Initial stroke management aims to restore cerebral blood flow in ischemic strokes and control bleeding in hemorrhagic strokes. Intravenous thrombolysis and endovascular thrombectomy are first-line treatments for eligible ischemic stroke patients, while hemorrhagic strokes may require surgical intervention.
Secondary prevention strategies include antiplatelet therapy, anticoagulation for atrial fibrillation, blood pressure control, cholesterol reduction, and lifestyle modifications. These interventions aim to reduce the risk of recurrent strokes.
Early stroke recognition and management are paramount in improving patient outcomes. As healthcare professionals, continuous education and training in stroke identification and treatment are essential to optimize patient care.
1.
Stem Cell Selection Unneeded for SSc Transplant Therapy?
2.
Radiation from CT scans could account for 5% of all cancer cases a year, study suggests
3.
Do I have prostate cancer? Why a simple PSA blood test alone won't give you the answer
4.
In Hemophilia A and B, a Novel Monoclonal Antibody Reduces Bleeding.
5.
Tumor infiltration of major blood vessels, not metastasis, may be primary cause of cancer death
1.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
2.
Emerging Dysregulated Signaling Pathways in Early-Onset Colorectal Cancer
3.
Exploring the Use of Bevacizumab in Treating Different Types of Cancers
4.
A Closer Look at Poorly Differentiated Carcinoma: Uncovering its Complexities
5.
Unlocking the Secrets of Squamous Cell Carcinoma: New Hope for Patients
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
2.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
3.
A New Era in Managing Cancer-Associated Thrombosis
4.
Navigating the Complexities of Ph Negative ALL - Part IX
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation